Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Italian multicentric non inferiority clinical study to verify whether the omission of axillary lymph node intervention in patients with SLN (Sentinel Lymph Nodes) ypN1mi after NAC (Neo Adiuvant Chemotherapy) does not lead to a significant deterioration in survival or in the risk of regional or distant recurrence, compared to patients with negative SLN (SLN ypN0) after NAC ,where the omission of axillary treatment is currently the standard treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek: 18-75 lat
- •Rak piersi z inwazyjnym typem histologicznym
- •Rozmiar guza: T1-T3
- •Przenlarged węzły chłonne w pachwie potwierdzone badaniem klinicznym i ultrasonografią
- •Chemioterapia neoadjuwantna przeprowadzona
- •Brak zmian w węzłach chłonnych w pachwie po chemioterapii
- •Brak przerzutów odległych
- •Brak wcześniejszego inwazyjnego raka piersi
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Rak zapalny piersi
- •Rak zawsze ograniczony do powierzchni (in situ)
- •Jednoczesny rak drugiej piersi
- •Choroby utrudniające leczenie uzupełniające
- •Choroby utrudniające regularne badania kontrolne
- •Inny rak w ciągu ostatnich 3 lat (z wyjątkiem zmian skórnych)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- April 19, 2021
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Istituto Clinico Humanitas
Rozzano, Italy
Trial contact
Corrado Tinterri, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.